Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability.

Giordano Novak Rossi, Isabella Caroline da Silva Dias, Glen Baker, José Carlos Bouso Saiz, Serdar M Dursun, Jaime E C Hallak, Rafael G Dos Santos

Expert opinion on drug safety 2022 Jun

filter terms:

Ayahuasca is a psychedelic brew originally used by Amazonian indigenous groups and in religious rituals. Pre-clinical and observational studies have demonstrated its possible potential as an antidepressant, and open- and placebo-controlled clinical trials corroborated these results. For it to become an approved treatment for depression, its safety and tolerability need to be assessed and documented. We have gathered data regarding the occurrence of adverse events (AEs) in all reported randomized, placebo-controlled trials with healthy and clinical populations involving ayahuasca administration (n = 108 ayahuasca administrations). We systematically categorized these results, recorded their prevalence, and discussed the possible mechanisms related to their emergence. There were no reports of serious AEs, indicating a relative safety of ayahuasca administration in controlled settings. Most common AEs included nausea, vomiting, headaches, and transient increases in cardiovascular measurements. Ayahuasca research is still in its infancy, especially concerning the absence of large and robust clinical trials to verify its antidepressant effects. Dose standardization, legal prohibition of the possession of its alkaloids and how traditional communities will be compensated if ayahuasca becomes an approved medicine are the biggest obstacles to overcome for its future use in the therapeutic context.

Citation

Giordano Novak Rossi, Isabella Caroline da Silva Dias, Glen Baker, José Carlos Bouso Saiz, Serdar M Dursun, Jaime E C Hallak, Rafael G Dos Santos. Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability. Expert opinion on drug safety. 2022 Jun;21(6):789-801